Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Taxes (2017 - 2020)

Avalo Therapeutics' Change in Taxes history spans 4 years, with the latest figure at $839000.0 for Q2 2020.

  • For Q2 2020, Change in Taxes rose 298.73% year-over-year to $839000.0; the TTM value through Mar 2021 reached $839000.0, up 146.25%, while the annual FY2020 figure was $288000.0, 119.45% up from the prior year.
  • Change in Taxes reached $839000.0 in Q2 2020 per AVTX's latest filing, up from -$551000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $3.2 million in Q3 2017 to a low of -$970852.0 in Q4 2017.
  • Average Change in Taxes over 4 years is $69972.6, with a median of -$190199.0 recorded in 2018.
  • Peak YoY movement for Change in Taxes: plummeted 3040.65% in 2019, then skyrocketed 298.73% in 2020.
  • A 4-year view of Change in Taxes shows it stood at -$970852.0 in 2017, then soared by 83.23% to -$162790.0 in 2018, then plummeted by 184.28% to -$462783.0 in 2019, then surged by 281.29% to $839000.0 in 2020.
  • Per Business Quant, the three most recent readings for AVTX's Change in Taxes are $839000.0 (Q2 2020), -$551000.0 (Q1 2020), and -$462783.0 (Q4 2019).